Skip to content

Validity of SOFA Score as Predictor of Mortality in Critically-ill Burn Patients

Validity of Sequential Organ Failure Assessment (SOFA) Score as Predictor of Mortality in Critically-ill Burn Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03930108
Enrollment
169
Registered
2019-04-29
Start date
2018-09-17
Completion date
2019-02-17
Last updated
2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mortality Prediction

Keywords

Burn injury, Mortality prediction, SOFA score, Organ failure

Brief summary

SOFA score is valid for mortality predictor for critically-ill patient in high care and intensive care burn unit

Interventions

OTHERSOFA score

Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adult patients (age 18 and above) who admitted to burn unit during sampling period

Exclusion criteria

* patients discharged or deceased less than 24 hours of admission * patients referred to other hospital within 30 days admission

Design outcomes

Primary

MeasureTime frameDescription
SOFA score Discrimination30 days from admissionSOFA score ability to discriminate outcomes based on variable scores: PaO2/FiO2; MAP/vasoactive treatment; serum creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS
SOFA score Calibration30 days from admissionSOFA score cutoff to predict outcome based on variable scores: PaO2/FiO2; MAP/vasoactive treatment; serum creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS
Correlation between SOFA score variables with outcome30 days from admissionCorrelation between patient outcomes with each SOFA score variable: PaO2/FiO2; MAP/vasoactive treatment; serum creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS

Secondary

MeasureTime frameDescription
SOFA score: Serum creatinine or 24-hour diuresisDay 1The score for serum creatinine or 24-hour diuresis variable cutoff: 0 point for creatinine \<1.2 mg/dL; 1. point for creatinine 1.2 - 1.9 mg/dL; 2. points for creatinine 2.0 - 3.4 mg/dL; 3. points for creatinine 3.5 - 4.9 mg/dL OR diuresis \<500 mL/24h; 4. points for creatinine \>5.0 mg/dL OR diuresis \<200 mL/24h.
SOFA score: Platelet countDay 1The score for platelet count variable cutoff: 0 point for \>=150 x10\^3/mm\^3; 1. point for \<150 x10\^3/mm\^3; 2. points for \<100 x10\^3/mm\^3; 3. points for \<50 x10\^3/mm\^3; 4. points for \<20 x10\^3/mm\^3.
Patient outcome30 days from admissionPatient outcome within 30 days of admission to burn units: deceased or survived
SOFA score: Glasgow Coma Scale (GCS)Day 1The score for GCS variable cutoff: 0 point for 15; 1. point for 13 - 14; 2. points for 10 - 12; 3. points for 6 - 9; 4. points for \<6L.
SOFA score: Serum BilirubinDay 1The score for serum bilirubin variable cutoff: 0 point for \<1.2 mg/dL; 1. point for 1.2 - 1.9 mg/dL; 2. points for 2.0 - 5.9 mg/dL; 3. points for 6.0 - 11.9 mg/dL; 4. points for \>12.0 mg/dL.
SOFA score: Partial Oxygen Pressure (PaO2)/ Fraction of Inspired Oxygen (FiO2)Day 1The score for PaO2/FiO2 variable cutoff: 0 point for \>400 mmHg; 1. point for \<400 mmHg; 2. points for \<300 mmHg; 3. points for \<200 mmHg with respiratory support; 4. points for \<100 mmHg with respiratory support.
SOFA score: Mean Arterial Pressure (MAP) or vasoactive agent usageDay 1The score for MAP or vasoactive agent usage variable cutoff: 0 point for MAP \>=70 mmHg; 1. point for MAP \<70 mmHg; 2. points for dopamine \<= 5 mcg/kg/min OR dobutamine any dose; 3. points for dopamine \>5 mcg/kg/min OR norepinephrine or epinephrine \<=0.1 mcg/kg/min; 4. points for dopamine \>15 mcg/kg/min OR norepinephrine or epinephrine \>0.1 mcg/kg/min.

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026